| Literature DB >> 26983372 |
Heng-Chih Pan1,2, Yu-Shan Chien3, Chang-Chyi Jenq1,4, Ming-Hung Tsai5,4, Pei-Chun Fan1, Chih-Hsiang Chang1, Ming-Yang Chang1,4, Ya-Chung Tian1,4, Ji-Tseng Fang1,4, Chih-Wei Yang1,4, Yung-Chang Chen1,4.
Abstract
Critically ill cirrhotic patients have high mortality rates, particularly when they present with acute kidney injury (AKI) on admission. The Kidney Disease: Improving Global Outcomes (KDIGO) group aimed to standardize the definition of AKI and recently published a new AKI classification. However, the efficacy of the KDIGO classification for predicting outcomes of critically ill cirrhotic patients is unclear. We prospectively enrolled 242 cirrhotic patients from a 10-bed specialized hepatogastroenterology intensive care unit (ICU) in a 2000-bed tertiary-care referral hospital. Demographic parameters and clinical variables on day 1 of admission were prospectively recorded. The overall in-hospital mortality rate was 62.8%. Liver diseases were usually attributed to hepatitis B viral infection (26.9%). The major cause of ICU admission was upper gastrointestinal bleeding (38.0%). Our result showed that the KDIGO classification had better discriminatory power than RIFLE and AKIN criteria in predicting in-hospital mortality. Cumulative survival rates at the 6-month after hospital discharge differed significantly between patients with and without AKI on ICU admission day. In summary, we identified that the outcome prediction performance of KDIGO classification is superior to that of AKIN or RIFLE classification in critically ill cirrhotic patients.Entities:
Mesh:
Year: 2016 PMID: 26983372 PMCID: PMC4794801 DOI: 10.1038/srep23022
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The definitions and classification for AKI.
| SCr criteria | UO Criteria | |
|---|---|---|
| (A) RIFLE | ||
| Definition | SCr changes over | UO < 0.5 ml/kg/h x 6 hrs |
| Risk | Increase in SCr ≥ 1.5 x baseline or decrease in GFR ≥ 25% | UO < 0.5 ml/kg/h x 6 hrs |
| Injury | Increase in SCr ≥ 2.0 x baseline or decrease in GFR ≥ 50% | UO < 0.5 ml/kg/h x 12 hrs |
| Failure | Increase in SCr ≥ 3.0 x baseline or an absolute serum creatinine ≥4.0 mg/dl with an acute rise of at least 0.5 mg/dl or or decrease in GFR ≥ 75% | UO < 0.5 ml/kg/h x 24 hrs or anuria x 12hrs |
| Loss | Complete loss of kidney function > 4 wks | |
| ESRD | End-stage renal disease (>3 mo) | |
| (B) AKIN | ||
| Definition | Acute SCr changes occur within a | Same as RIFLE |
| Stage 1 | ||
| Stage 2 | Increase in SCr to 2.0–2.9 x baseline | |
| Stage 3 | Increase in SCr ≥ 3.0 x baseline or SCr ≥ 4.0 mg/dl with an acute rise of at least 0.5 mg/dl or | |
| (C) KDIGO | ||
| Definition | SCr changes ≥ 1.5 x baseline to have occurred within the prior 7 days or a 0.3 mg/d lincrease in SCr must occur within a 48 hrs period | Same as RIFLE |
| Stage 1 | Increased in SCr ≥ 1.5 x baseline or of 0.3 mg/dl | |
| Stage 2 | Increase in SCr ≥ 2.0 x baseline | |
| Stage 3 | Increase in SCr ≥ 3.0 x baseline or | |
*Abbreviations: SCr, serum creatinine; UO, urine output; hrs, hours; wks, weeks; ESRD, end-stage renal disease; RRT, renal replacement therapy; RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes.
Patients’ demographic data and clinical characteristics.
| All patients (n = 242) | Survivors (n = 90) | Non-survivors (n = 152) | p-value | |
|---|---|---|---|---|
| Age (years) | 58 ± 14 | 58 ± 14 | 58 ± 14 | NS (0.775) |
| Gender (M/F) | 183/59 | 72/18 | 111/41 | NS (0.278) |
| Body weight (kg) | 65.2 ± 12.7 | 65.3 ± 12.6 | 65.1 ± 12.8 | NS (0.919) |
| Length of ICU stay (days) | 8 ± 8 | 6 ± 6 | 9 ± 9 | |
| Length of hospital stay (days) | 26 ± 24 | 29 ± 28 | 24 ± 22 | NS (0.093) |
| MAP, ICU admission (mmHg) | 72.3 ± 15.6 | 78.8 ± 14 | 68 ± 15 | |
| Glasgow coma scale, ICU admission | 9 ± 5 | 11 ± 5 | 8 ± 5 | |
| Serum Creatinine, ICU first day (mg/dl) | 2.6 ± 2.1 | 1.6 ± 1.3 | 3.2 ± 2.1 | |
| Leukocytes, ICU first day (10^3/dl) | 13.0 ± 7.9 | 10.8 ± 6.3 | 14.4 ± 8.5 | |
| Hemoglobin, ICU first day (g/dl) | 9.1 ± 2.1 | 9.1 ± 2.0 | 9.1 ± 2.2 | NS (0.940) |
| Platelets, ICU first day (x10^9/l) | 95 ± 74 | 90 ± 55 | 98 ± 83 | NS (0.422) |
| Albumin, ICU first day (g/dl) | 2.5 ± 0.6 | 2.6 ± 0.6 | 2.4 ± 0.5 | |
| Sodium, ICU first day (mmol/l) | 137 ± 10 | 138 ± 8 | 137 ± 10 | NS (0.292) |
| Bilirubin, ICU first day (mg/dl) | 10.2 ± 11.1 | 4.7 ± 6.5 | 13.9 ± 11.9 | |
| Prothrombin time INR, ICU first day | 2.3 ± 1.5 | 1.7 ± 0.5 | 2.7 ± 1.8 | |
| AST, ICU first day | 179 ± 501 | 95 ± 176 | 228 ± 613 | |
| ALT, ICU first day (units/l) | 518 ± 1962 | 212 ± 412 | 704 ± 2450 | |
| DM (yes/no) | 72/170 | 32/58 | 40/112 | NS (0.147) |
| Hepatic encephalopathy (yes/no) | 151/91 | 47/43 | 104/48 | |
| Previous ascites (yes/no) | 186/56 | 68/22 | 118/34 | NS (0.753) |
| Previous SBP (yes/no) | 53/189 | 13/77 | 40/112 | |
| Previous EV bleeding (yes/no) | 134/108 | 58/32 | 76/76 | |
| Previous peptic ulcer bleeding (yes/no) | 85/157 | 29/61 | 56/96 | NS (0.489) |
| Previous hepatoma (yes/no) | 74/168 | 27/63 | 47/105 | NS (1.000) |
| Previous renal failure (yes/no) | 63/179 | 18/72 | 45/107 | NS (0.129) |
| Respiratory failure, ICU first day (yes/no) | 151/91 | 49/41 | 102/50 | NS (0.055) |
| Sepsis, ICU admission (yes/no) | 116/71 | 32/24 | 84/47 | NS (0.412) |
| Child-Pugh points | 11 ± 2 | 10 ± 2 | 12 ± 2 | <0.001 |
| MELD score | 28 ± 12 | 19 ± 7 | 33 ± 10 | |
| APACHE II | 25 ± 9 | 20 ± 7 | 28 ± 9 | |
| APACHE III | 105 ± 40 | 78 ± 31 | 121 ± 35 | |
| SOFA | 11 ± 5 | 7 ± 3 | 13 ± 4 |
Abbreviation: M, male; F, female; ICU, intensive care unit; MAP, mean arterial pressure; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DM, diabetes mellitus; SBP, spontaneous bacterial peritonitis; EV, esophageal varices; MELD, model for end-stage liver disease; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organfailure assessment.
Values in bold are statistically significant (P-value < 0.05).
There were significant differences in length of ICU stay, mean arterial pressure, Glasgow coma scale, serum creatinine, albumin, bilirubin, AST, ALT, prothrombin time INR, leukocyte count, presence of hepatic encephalopathy, previous SBP, previous EV bleeding, liver and ICU prognostic scores.
Causes of cirrhosis and reasons of ICU admission according to hospital survival.
| All patients (n = 242) | Survivors (n = 90) | Non-survivors (n = 152) | p-value | |
|---|---|---|---|---|
| Causes of cirrhosis | ||||
| Alcoholic | 54 (22.3%) | 24 (26.7%) | 30 (19.7%) | NS (0.263) |
| Hepatitis B | 65 (26.9%) | 19 (21.1%) | 46 (30.3%) | NS (0.135) |
| Hepatitis C | 52 (21.5%) | 21 (23.3%) | 31 (20.4%) | NS (0.629) |
| Alcoholic + Hepatitis B | 30 (12.4%) | 8 (8.9%) | 22 (14.5%) | NS (0.231) |
| Alcoholic + Hepatitis C | 7 (2.9%) | 4 (4.4%) | 3 (2.0%) | NS (0.429) |
| Hepatitis B + Hepatitis C | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Alcoholic + Hepatitis B + Hepatitis C | 6 (2.5%) | 1 (1.1%) | 5 (3.3%) | NS (0.416) |
| Other causesa | 28 (11.6%) | 13 (14.4%) | 15 (9.9%) | NS (0.303) |
| Primary ICU admission | ||||
| Severe UGI bleeding | 92 (38.0%) | 46 (51.1%) | 46(30.3%) | |
| Hepatic encephalopathy | 60 (24.8%) | 26 (28.9%) | 34 (22.4%) | NS (0.283) |
| Respiratory failure | 28 (11.6%) | 6 (6.7%) | 22 (14.5%) | NS (0.095) |
| Severe sepsis | 47 (19.4%) | 7 (7.8%) | 40 (26.3%) | |
| HCC rupture | 10 (4.1%) | 4 (4.4%) | 6 (3.9%) | NS (1.000) |
| Acute pancreatitis | 2 (0.8%) | 0 (0%) | 2 (1.3%) | NS (0.531) |
| Acute renal failure | 6 (2.5%) | 1 (1.1%) | 5 (3.3%) | NS (0.416) |
Abbreviation: HCC, hepaocellular carcinoma; ICU, intensive care unit; UGI, upper gastrointestinal;
a “Other causes” includes primary biliary cirrhosis, autoimmune hepatitis, andother unknown causes.
Values in bold are statistically significant (P-value < 0.05).
Cause of cirrhosis: none of the causes was independently associated with in-hospital mortality.
Primary ICU admission reason: sever UGI bleeding and severe sepsis were independently associated with in-hospital mortality.
Survivors and non-survivors in different scoring system.
| All patients (n = 242) | Survivors (n = 90) | Non-survivors (n = 152) | p-value | |
|---|---|---|---|---|
| AKIN | ||||
| No AKI | 90 (37%) | 55 (61%) | 35 (23%) | |
| AKI | 152 (63%) | 35 (39%) | 117 (77%) | |
| Stage I | 15 (6%) | 7 (8%) | 8 (5%) | NS (0.286) |
| Stage II | 40 (17%) | 13 (14%) | 27 (18%) | NS (0.436) |
| Stage III | 97 (40%) | 15 (17%) | 82 (54%) | |
| RIFLE | ||||
| No AKI | 84 (35%) | 58 (64%) | 26 (18%) | |
| AKI | 158 (65%) | 32 (36%) | 126 (82%) | |
| Risk | 13 (5%) | 5 (6%) | 8 (5%) | NS (1.000) |
| Injury | 40 (17%) | 12 (13%) | 28 (18%) | NS (0.284) |
| Failure | 105 (43%) | 15 (17%) | 90 (59%) | |
| KDIGO | ||||
| No AKI | 79 (33%) | 57 (63%) | 22 (14%) | |
| AKI | 163 (67%) | 33 (37%) | 130 (86%) | |
| Stage I | 16 (7%) | 6 (7%) | 10 (7%) | NS (1.000) |
| Stage II | 40 (17%) | 12 (13%) | 28 (18%) | NS (0.284) |
| Stage III | 107 (44%) | 15 (17%) | 92 (61%) |
Abbreviation: AKI, acute kidney injury; RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes; NS, not significant
Values in bold are statistically significant (P-value < 0.05).
Correlation between scoring systems on the first day of ICU admission (Spearman rank correlation coefficients: r).
| Scores | AKIN | RIFLE |
|---|---|---|
| RIFLE | 0.903** | – |
| KDIGO | 0.903** | 0.988** |
Abbreviation: RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes
**p < 0.01.
Comparison of calibration and discrimination of the AKI scores in predicting hospital mortality.
| Calibration | Discrimination | |||||
|---|---|---|---|---|---|---|
| Hosmer-Lemeshow χ2 | df | p | AUROC ± SE | 95% CI | p | |
| AKIN | 1.739 | 2 | 0.419 | 0.741 ± 0.033 | 0.675–0.806 | |
| RIFLE | 2.302 | 2 | 0.316 | 0.774 ± 0.032 | 0.712–0.837 | |
| KDIGO | 2.473 | 2 | 0.290 | 0.781 ± 0.032 | 0.719–0.843 | |
Abbreviation: RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes; df, degree of freedom; AUROC, areas under the receiver operating characteristic curve; SE, standard error; CI, confidence intervals
Values in bold are statistically significant (P-value < 0.05).
Odds Ratio of AKI stages in predicting hospital mortality according to AKIN, RIFLE, and KDIGO criteria.
| Score | n | Hospital mortality (%) | Beta coefficient | Standard error | Odds rations (95% CI) | p |
|---|---|---|---|---|---|---|
| AKIN | ||||||
| No AKI | 90 | 39 | – | – | 1 (reference) | – |
| AKIN-1 | 15 | 53 | 0.097 | 0.950 | 1.101 (0.171–7.094) | 0.919 |
| AKIN-2 | 40 | 68 | 1.275 | 0.438 | 3.580 (1.518–8.442) | |
| AKIN-3 | 97 | 85 | 2.188 | 0.386 | 8.922 (4.189–19.002) | |
| Constant | – | – | −0.502 | 0.264 | 0.605 | 0.057 |
| RIFLE | ||||||
| No AKI | 84 | 31 | – | – | 1 (reference) | – |
| RIFLE-R | 13 | 62 | 1.312 | 0.618 | 3.112 (1.105–12.470) | |
| RIFLE-I | 40 | 70 | 1.689 | 0.420 | 5.413 (2.377–12.327) | |
| RIFLE-F | 105 | 86 | 2.644 | 0.367 | 14.075 (6.852–28.911) | |
| Constant | – | – | −0.842 | 0.239 | 0.431 | |
| KDIGO | ||||||
| No AKI | 79 | 28 | – | – | 1 (reference) | – |
| KDIGO-1 | 16 | 63 | 1.153 | 0.592 | 3.167 (0.992–10.111) | |
| KDIGO-2 | 40 | 70 | 1.712 | 0.422 | 5.542 (2.422–12.677) | |
| KDIGO-3 | 107 | 86 | 2.679 | 0.370 | 14.567 (7.057–30.070) | |
| Constant | – | – | −0.865 | 0.243 | 0.421 | |
Abbreviation: AKI, acute kidney injury, RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes.
Values in bold are statistically significant (P-value < 0.05).
Figure 1Survival Functions.
Kaplan-Meier survival analysis for 242 critically ill cirrhotic patients according to the 3 AKI classifications on the first day of ICU admission. (a) Based on the KDIGO classification, the 180-day cumulative survival rates differed significantly for patients without AKI versus patients with KDIGO stages 1 to 3 (p < 0.001). The comparisons between patients with KDIGO stage 1 and those with KDIGO stages 2 to 3, and between patients with KDIGO stages 2 and those with KDIGO stage 3 have been depicted on the figure. (b) Based on the AKIN classification, the 180-day cumulative survival rates differed significantly for patients without AKI versus patients with AKIN stages 1 to 3, p < 0.001). The comparisons between patients with AKIN stage 1 and those with AKIN stages 2 to 3, and between patients with AKIN stages 2 and those with AKIN stage 3 have been depicted on the figure. (c) Based on the RIFLE classification, the 180-day cumulative survival rates differed significantly for patient without AKI versus patients with RIFLE-R, RIFLE-I, and RIFLE-F (p < 0.001). The comparisons between patients with RIFLE-R and those with RIFLE-I to F, and between patients with RIFLE-I and those with RIFLE-F have been depicted on the figure. (d) Patients with AKI diagnosed according to KDIGO but missed by AKIN or RIFLE classification had significantly lower hospital survival rate than patients without AKI (Log Rank P < 0.001). (e) Patients with AKI diagnosed according to KDIGO but missed by AKIN or RIFLE classification had significantly lower 180-day cumulative survival rate than patients without AKI (Log Rank P = 0.001). * Abbreviation: AKI, acute kidney injury; RIFLE, risk of renal failure, injury to kidney, failure of kidney function, loss of kidney function, and end-stage renal failure; AKIN, acute kidney injury network; KDIGO, kidney disease improving global outcomes.